---

Management Plan: Venu, 51M — T2DM + HTN + Dyslipidemia + Alcoholic

Summary of Key Findings

---

1. GLYCEMIC MANAGEMENT

Pharmacological Plan

• Insulin: Basal insulin (e.g., Insulin Glargine 10 units SC at bedtime, titrate by 2 units every 3 days to achieve FBS <130 mg/dL) + consider premix (30/70) or basal-bolus if needed
• Metformin: 500 mg BD with meals → uptitrate to 1000 mg BD over 4 weeks (improves insulin sensitivity, weight neutral, affordable)
  • Caution: Alcohol use + elevated ALP → check liver function fully before high-dose metformin; avoid if hepatic failure develops

• Lowers glucose insulin-independently
• Reduces systolic BP by 3–6 mmHg (addresses hypertension)
• Cardiorenal protective (reduces CV mortality in T2DM)
• Also promotes modest weight loss and lowers triglycerides modestly

• GLP-1 RAs / DPP-4 inhibitors: Contraindicated or use with caution — heavily elevated triglycerides (324) + alcohol use = high pancreatitis risk; Harrison's explicitly states "avoid in patients with heavy alcohol use, severely elevated serum triglycerides" — Harrison's Principles of Internal Medicine 22E
• Sulfonylureas: May use as add-on (e.g., Glimepiride 1–2 mg with breakfast) but risk of hypoglycemia; acceptable if cost is a concern
• Thiazolidinediones (pioglitazone): Avoid — worsens edema, risk of heart failure; HDL raising effect is minor

• HbA1c < 7.0% (reasonable for his age/profile)
• FBS: 80–130 mg/dL; PPBS: <180 mg/dL

---

2. ANTIHYPERTENSIVE MANAGEMENT

• Target BP: <130/80 mmHg in diabetic hypertensives
• First-line: ACE Inhibitor (e.g., Ramipril 5–10 mg OD) or ARB (Losartan/Telmisartan)
  • Preferred in diabetics for renoprotection (reduces microalbuminuria/proteinuria)
  • Check urine microalbumin/creatinine ratio — likely already present given the profile
• Add-on if needed: Amlodipine 5 mg OD (CCB — safe, no metabolic issues)
• Avoid: Beta-blockers as monotherapy (mask hypoglycemia symptoms); Thiazides at high dose (worsen hyperglycemia and triglycerides)

---

3. DYSLIPIDEMIA MANAGEMENT

• Alcohol cessation is the single most impactful intervention — alcohol directly drives hypertriglyceridemia and fatty liver
• Fibrates: Fenofibrate 145 mg OD — first-line for hypertriglyceridemia
  • Reduces TG 40–50%, raises HDL modestly
  • If TG were >500, emergency risk of pancreatitis
• Glycemic control itself will lower TG substantially

• Diabetic + hypertensive + male age 51 = HIGH cardiovascular risk
• High-intensity statin mandatory: Atorvastatin 40–80 mg OD (regardless of LDL)
• Per Harrison's: "Almost all treatment studies of diabetic dyslipidemia have been performed in type 2 DM… interventional therapies reduce ASCVD events" — Harrison's 22E
• Statin + fibrate combination: Use cautiously; avoid Gemfibrozil with statins (myopathy risk); Fenofibrate safer combination partner

---

4. ALCOHOL COUNSELING & LIFESTYLE

• Alcohol cessation — mandatory and urgent:
  • Directly worsens: hyperglycemia, hypertriglyceridemia, liver disease (ALP 133 already elevated), hypertension
  • Mildly elevated ALP in an alcoholic → Alcoholic fatty liver / early alcoholic hepatitis; check AST:ALT ratio (if >2:1, confirms alcoholic etiology)
  • Refer to de-addiction counseling / support group
• Diet: Low-carbohydrate, low-saturated fat, low-alcohol diet; caloric restriction if overweight
• Exercise: Minimum 150 min/week moderate aerobic activity (reduces insulin resistance, lowers TG, raises HDL)
• Weight reduction if BMI elevated

---

5. MONITORING & INVESTIGATIONS TO ORDER NOW

---

6. DRUG SUMMARY (Proposed Regimen)

---

Key Priorities in Order

1. Alcohol cessation — addresses glucose, TG, BP, and liver simultaneously
2. Initiate insulin — glucose too high for oral agents alone
3. ACE inhibitor — hypertension + renoprotection
4. Statin — non-negotiable cardiovascular risk reduction
5. Fenofibrate — for TG 324 mg/dL (pancreatitis risk)
6. Avoid GLP-1 RA/DPP-4 inhibitors — pancreatitis risk with alcohol + high TG
7. Lifestyle modification + monitoring